Study of (Telintra®) in Non-Del(5q) Myelodysplastic Syndrome

Summary

This is a multicenter, single arm open label Phase 2b Study of oral ezatiostat (Telintra®) in Patients who are RBC tranfusion dependent, Low to INT-1 IPSS risk, non-del (5q) Myelodysplastic Syndrome (MDS).

Timeline

Start

2011-10

Primary completion

2013-02

Completion

2013-02

Outcome

Outcome not reported

Stopped (Business): “Study TLK199.2108 was terminated for business reasons.”

Drugs

Indications